Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients
Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The fixed-dose combination of sofosbuvir and daclatasvir in a single pill is being used for
the treatment of hepatitis C in Iran. In this study the efficacy of this combination is
evaluated in 1000 patient with hepatitis C.